Alembic Pharmaceuticals
Alembic Pharmaceuticals Ltd., a prominent player in the global pharmaceutical industry, is headquartered in Vadodara, India. Founded in 1907, the company has established itself as a leader in the development and manufacturing of generic and branded pharmaceuticals, with a strong presence in both domestic and international markets. Specialising in a diverse range of therapeutic areas, Alembic is known for its high-quality formulations and active pharmaceutical ingredients (APIs). The company has achieved significant milestones, including numerous approvals from regulatory authorities worldwide, which underscore its commitment to quality and innovation. Alembic's extensive portfolio includes a variety of products that cater to chronic and acute conditions, setting it apart in a competitive landscape. With a robust market position, Alembic Pharmaceuticals continues to expand its reach, driven by a dedication to research and development, ensuring it remains at the forefront of the pharmaceutical sector.
DitchCarbon Score
How does Alembic Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alembic Pharmaceuticals's score of 24 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alembic Pharmaceuticals's reported carbon emissions
In 2023, Alembic Pharmaceuticals reported total carbon emissions of approximately 86096,000 kg CO2e for Scope 1, 83482,000 kg CO2e for Scope 2, and a significant 644996000 kg CO2e for Scope 3 emissions. This indicates a comprehensive approach to tracking emissions across all scopes, with Scope 3 emissions representing the largest share, primarily driven by purchased goods and services (454402000 kg CO2e) and employee commuting (36383000 kg CO2e). The company has committed to achieving net-zero emissions by 2050, as part of its long-term climate strategy. This commitment encompasses all scopes of emissions, reflecting a proactive stance in addressing climate change. Alembic Pharmaceuticals is currently in the process of establishing near-term reduction targets, demonstrating its dedication to sustainability within the pharmaceuticals sector. In 2022, the company reported Scope 1 emissions of 41213000 kg CO2e and Scope 2 emissions of 132604000 kg CO2e, indicating a clear trajectory of emissions management. The emission intensity metrics, such as total Scope 1 and Scope 2 emissions per rupee of turnover, further illustrate the company's efforts to integrate sustainability into its operational framework. Overall, Alembic Pharmaceuticals is taking significant steps towards reducing its carbon footprint and aligning with global climate goals, positioning itself as a responsible player in the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 41,213,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 132,604,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alembic Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
